喜报！麦科奥特MT1013 Ⅲ期临床研究，顺利完成全部试验参与者入组！

MICOT

本研究自2025年9月迎来重要突破：当月顺利完成首家研究中心启动，同步实现首例试验参与者入组，正式拉开Ⅲ期临床研究的序幕。此后，在全国100余家研究中心的鼎力支持、临床研究者的严谨履职，以及麦科奥特项目团队的通力协作下，我们高效推进各项研究工作，全力保障入组流程的规范与顺畅。

截至2026年4月10日，本研究顺利完成第435例试验参与者入组，标志着整个入组阶段圆满收官！从首例入组到末例入组，仅用时6个月，较原计划提前20余天，用专业与效率，彰显了麦科奥特在创新药研发领域的硬实力，也凝聚着所有参与者的心血与付出。

此次入组里程碑的顺利达成，不仅是MT1013临床研究进程中的重要节点，更为该产品后续上市申报进一步打下坚实基础。接下来，研究重心将正式转移至下一阶段——试验参与者随访与数据清理工作。

This study achieved a major breakthrough in September 2025, when the first site was initiated and the first participant was enrolled, marking the official start of the Phase Ⅲ clinical trial. Since then, with the strong support of over 100 clinical trial centers nationwide, the rigorous efforts of the clinical investigators, and the close collaboration of the Micot project team, we have efficiently advanced all research activities and ensured the standardization and smoothness of the enrollment process.

As of April 10, 2026, the study has completed the enrollment of the 435th trial participant, marking the successful conclusion of the entire enrollment phase. From the enrollment of the first participant to the last, it took only six months – more than 20 days ahead of schedule. This achievement demonstrates Micot’s strength in innovative drug R&D through professionalism and efficiency, and embodies the dedication and hard work of all participants.

The successful completion of this enrollment milestone is not only a key step in the MT1013 clinical research process but also further solidifies the foundation for the product’s future NDA submission. Moving forward, the focus of the study will officially shift to the next phase: participant follow-up and data cleaning.